CO6260081A2 - Un medicamento para tratar o prevenir trastornos metabolicos que contiene un agonista nachr (alfa)7 selectivo - Google Patents
Un medicamento para tratar o prevenir trastornos metabolicos que contiene un agonista nachr (alfa)7 selectivoInfo
- Publication number
- CO6260081A2 CO6260081A2 CO10024587A CO10024587A CO6260081A2 CO 6260081 A2 CO6260081 A2 CO 6260081A2 CO 10024587 A CO10024587 A CO 10024587A CO 10024587 A CO10024587 A CO 10024587A CO 6260081 A2 CO6260081 A2 CO 6260081A2
- Authority
- CO
- Colombia
- Prior art keywords
- agonist
- nachr
- treat
- selective
- compound
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 6
- 208000030159 metabolic disease Diseases 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 7
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 abstract 5
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000001421 hyperglycemia Diseases 0.000 abstract 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95361407P | 2007-08-02 | 2007-08-02 | |
| US95361307P | 2007-08-02 | 2007-08-02 | |
| US95361007P | 2007-08-02 | 2007-08-02 | |
| US97165407P | 2007-09-12 | 2007-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260081A2 true CO6260081A2 (es) | 2011-03-22 |
Family
ID=39945177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10024587A CO6260081A2 (es) | 2007-08-02 | 2010-03-02 | Un medicamento para tratar o prevenir trastornos metabolicos que contiene un agonista nachr (alfa)7 selectivo |
| CO10024579A CO6260080A2 (es) | 2007-08-02 | 2010-03-02 | (2s,3r)-n-(2-((3-piridinil)metil)-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sal novedosas y metodos de uso de los mismos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10024579A CO6260080A2 (es) | 2007-08-02 | 2010-03-02 | (2s,3r)-n-(2-((3-piridinil)metil)-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sal novedosas y metodos de uso de los mismos |
Country Status (35)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US8314119B2 (en) * | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| EP2647373A1 (en) * | 2008-05-12 | 2013-10-09 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine. |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| JP5749797B2 (ja) | 2010-05-17 | 2015-07-15 | フォルム ファーマシューティカルズ、インコーポレイテッド | （ｒ）−７−クロロ−ｎ−（キヌクリジン−３−イル）ベンゾ［ｂ］チオフェン−２−カルボキサミド塩酸塩一水和物の結晶形 |
| RU2013108223A (ru) * | 2010-07-26 | 2014-09-10 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных нарушений определенными агонистами рецептора никотиновой кислоты альфа-7 в сочетании с ингибиторами ацетилхолинэстеразы |
| CA2809675A1 (en) | 2010-09-23 | 2012-03-29 | Shuang Chen | Monohydrate of an azaadamantane derivative |
| TW201242600A (en) * | 2011-01-18 | 2012-11-01 | Targacept Inc | Treatment of cognitive dysfunction in schizophrenia |
| US20140171448A1 (en) | 2011-01-27 | 2014-06-19 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
| PL3156056T3 (pl) | 2011-03-18 | 2024-04-29 | Alkermes Pharma Ireland Limited | Kompozycje farmaceutyczne zawierające estry sorbitanu |
| US20140228398A1 (en) | 2011-03-18 | 2014-08-14 | Novartis Ag | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE |
| WO2012129262A1 (en) * | 2011-03-23 | 2012-09-27 | Targacept, Inc. | Treatment of attention deficit/hyperactivity disease |
| JPWO2013002365A1 (ja) | 2011-06-30 | 2015-02-23 | 東レ株式会社 | 止痒剤 |
| TW201311698A (zh) * | 2011-08-22 | 2013-03-16 | Targacept Inc | 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷 |
| BR112014007485B1 (pt) | 2011-10-20 | 2022-05-31 | Novartis Ag | Métodos para prever responsividade terapêutica de um indivíduo a tratamento com um ativador do receptor de acetilcolina nicotínico alfa 7, e usos do referido ativador |
| NZ630703A (en) * | 2012-03-19 | 2017-02-24 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising glycerol esters |
| JP6333802B2 (ja) | 2012-03-19 | 2018-05-30 | アルカームス ファーマ アイルランド リミテッド | ベンジルアルコールを含む医薬組成物 |
| JP6471089B2 (ja) | 2012-03-19 | 2019-02-13 | アルカームス ファーマ アイルランド リミテッド | 脂肪酸エステルを含む医薬組成物 |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| AU2013349388B2 (en) | 2012-09-19 | 2018-06-28 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| CN104837499B (zh) | 2012-12-11 | 2018-02-23 | 诺华有限公司 | 预测对α7烟碱型乙酰胆碱受体激活剂治疗响应性的生物标志物 |
| JP6137336B2 (ja) | 2013-01-15 | 2017-05-31 | ノバルティス アーゲー | ナルコレプシーの処置のためのアルファ７ニコチン性受容体アゴニストの使用 |
| US20150313884A1 (en) | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| WO2014111837A1 (en) | 2013-01-15 | 2014-07-24 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| CA2898080C (en) | 2013-01-15 | 2018-01-09 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
| WO2014153424A1 (en) * | 2013-03-19 | 2014-09-25 | La Jolla Institute For Allergy And Immunology | Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins) |
| RU2688233C2 (ru) | 2014-03-20 | 2019-05-21 | Алкермес Фарма Айэленд Лимитед | Препараты арипипразола, имеющие повышенные скорости впрыска |
| AU2015240465B2 (en) | 2014-04-04 | 2020-02-27 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| CN104288771B (zh) * | 2014-09-30 | 2017-03-15 | 郑州大学第五附属医院 | α7nAChR激动剂的新用途 |
| US10857140B2 (en) | 2015-05-06 | 2020-12-08 | The Regents Of The University Of California | K-Ras modulators |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| US10282666B1 (en) | 2015-11-10 | 2019-05-07 | Google Llc | Coherency detection and information management system |
| RU2675111C2 (ru) * | 2017-03-31 | 2018-12-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" | Способ стимуляции нейрогенеза в гиппокампе |
| AU2018255413A1 (en) | 2017-04-20 | 2019-12-05 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203990A (en) | 1979-04-30 | 1980-05-20 | G. D. Searle & Co. | Anti-diarrheal 2-substituted quinuclidines |
| EP0353189B1 (de) | 1988-07-28 | 1994-01-12 | Ciba-Geigy Ag | Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung |
| US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
| EP0402056A3 (en) | 1989-06-06 | 1991-09-04 | Beecham Group p.l.c. | Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| EP0412798A3 (en) | 1989-08-08 | 1992-07-01 | Merck Sharp & Dohme Ltd. | Substituted pyridines, their preparation, formulations and use in dementia |
| IN173570B (enExample) | 1989-11-23 | 1994-06-04 | Pfizer | |
| DK40890D0 (da) | 1990-02-16 | 1990-02-16 | Ferrosan As | Substituerede urinstofforbindelser, deres fremstilling og anvendelse |
| EP0492903A1 (en) | 1990-12-21 | 1992-07-01 | MERCK SHARP & DOHME LTD. | Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma |
| KR0175638B1 (ko) | 1991-03-01 | 1999-02-18 | 카렌 에이.홀브루크 | 신경계 퇴행성 질환 치료용 니코틴 아날로그의 개량된 제조방법 |
| US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| US5276043A (en) | 1992-04-10 | 1994-01-04 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
| KR100272614B1 (ko) | 1992-08-31 | 2000-11-15 | 엠. 잭 오해니언 | 신경계의 퇴행성 질환의 치료에 유용한 아나바세인 유도체 |
| US5977144A (en) | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| IL109451A0 (en) * | 1993-04-29 | 1994-07-31 | Zeneca Ltd | Heterocyclic derivatives |
| AU7474794A (en) | 1993-07-22 | 1995-02-20 | E.I. Du Pont De Nemours And Company | Arthropodicidal azacyclic heterocycles |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5510355A (en) | 1994-09-06 | 1996-04-23 | Bencherif; Merouane | Depolarizing skeletal muscle relaxants |
| US5998404A (en) | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5824692A (en) | 1995-01-06 | 1998-10-20 | Lippiello; Patrick Michael | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| WO1996025160A1 (en) | 1995-02-17 | 1996-08-22 | Novo Nordisk A/S | The use of heterocyclic compounds |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| JPH11508540A (ja) | 1995-06-29 | 1999-07-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の置換アザ環式またはアザ二環式化合物 |
| JPH11512443A (ja) | 1995-09-22 | 1999-10-26 | ノボ ノルディスク アクティーゼルスカブ | 新規な置換アザ環式またはアザ二環式化合物 |
| US5712270A (en) | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US5811442A (en) | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| KR100589872B1 (ko) | 1997-05-30 | 2006-06-15 | 뉴로서치 에이/에스 | 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법 |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| US5952339A (en) | 1998-04-02 | 1999-09-14 | Bencherif; Merouane | Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| DK1068208T3 (da) | 1998-04-02 | 2003-09-01 | Targacept Inc | Azatricyclo[3.3.1.1]dekanderivater og farmaceutiske sammensætninger, der indeholder dem |
| ATE255888T1 (de) | 1998-06-01 | 2003-12-15 | Ortho Mcneil Pharm Inc | Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten |
| US6310043B1 (en) | 1998-08-07 | 2001-10-30 | Governors Of The University Of Alberta | Treatment of bacterial infections |
| GB9821503D0 (en) | 1998-10-02 | 1998-11-25 | Novartis Ag | Organic compounds |
| US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| US6734215B2 (en) | 1998-12-16 | 2004-05-11 | University Of South Florida | Exo-S-mecamylamine formulation and use in treatment |
| SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| SE9904176D0 (sv) * | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| BR0112297A (pt) | 2000-06-27 | 2003-05-06 | S A L V A T Lab Sa | Compostos carbamatos derivados de arilalquilaminas |
| AU2001282873A1 (en) * | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| WO2002016356A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| WO2002016358A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| WO2002017358A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| JP2004506734A (ja) | 2000-08-21 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリド置換ヘテロアリール部分 |
| US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| EP1345937B1 (en) | 2000-12-22 | 2005-09-28 | Almirall Prodesfarma AG | Quinuclidine carbamate derivatives and their use as m3 antagonists |
| US20020086871A1 (en) * | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
| SI1397366T1 (sl) | 2001-06-01 | 2007-06-30 | Astrazeneca Ab | Nov ligand za nikotinske acetilholinske receptorje, koristen v terapiji |
| US6569865B2 (en) * | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| WO2003011837A1 (en) | 2001-08-01 | 2003-02-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6562816B2 (en) | 2001-08-24 | 2003-05-13 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease |
| BR0212123A (pt) | 2001-08-24 | 2004-07-20 | Upjohn Co | 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças |
| EP1425286B1 (en) | 2001-09-12 | 2007-02-28 | Pharmacia & Upjohn Company LLC | Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
| CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| MXPA04007083A (es) | 2002-02-20 | 2004-10-29 | Upjohn Co | Compuestos azabiciclicos para el tratamiento de enfermedades. |
| DE60333746D1 (de) * | 2002-04-18 | 2010-09-23 | Astrazeneca Ab | Thienylverbindungen |
| US7417049B2 (en) | 2002-04-18 | 2008-08-26 | Astrazeneca Ab | Furyl compounds |
| EP1499616B1 (en) | 2002-04-18 | 2009-06-17 | AstraZeneca AB | Heterocyclic compounds |
| US7176198B2 (en) * | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| SE0202465D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New compounds |
| ATE384720T1 (de) | 2002-08-14 | 2008-02-15 | Neurosearch As | Chinucledin - derivate und deren verwendung |
| SE0202430D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | New Compounds |
| JP2006501246A (ja) | 2002-08-30 | 2006-01-12 | メモリー・ファーマシューティカルズ・コーポレイション | 神経変性疾患の治療において有用なアナバセイン誘導体 |
| AU2003276919B2 (en) | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| BR0315056A (pt) | 2002-11-01 | 2005-08-16 | Pharmacia & Upjohn Co Llc | Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central |
| WO2004039366A1 (en) | 2002-11-01 | 2004-05-13 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| CN1735414A (zh) | 2002-12-06 | 2006-02-15 | 北岸长岛犹太人研究学院 | 用α7受体结合类胆碱激动剂抑制炎症 |
| HRP20050522A2 (en) | 2002-12-11 | 2005-12-31 | Pharmacia & Upjohn Company Llc | Combination for the treatment of adhd |
| MXPA05005666A (es) | 2002-12-11 | 2005-07-26 | Pharmacia & Upjohn Co Llc | Tratamiento de enfermedades con combinaciones de agonistas del receptor nicotinico de acetilcolina alfa-7 y otros compuestos. |
| US6917746B2 (en) | 2002-12-17 | 2005-07-12 | 3M Innovative Properties Company | Apparatus and method for creating a fiber optic circuit |
| US6777617B2 (en) | 2002-12-30 | 2004-08-17 | 3M Innovative Properties Company | Telecommunications terminal |
| MXPA05006861A (es) | 2003-02-27 | 2005-12-12 | Neurosearch As | Derivados arildiazabiciclicos novedosos. |
| CN1829721A (zh) | 2003-07-08 | 2006-09-06 | 阿斯利康(瑞典)有限公司 | 对α7烟碱乙酰胆碱受体具有亲和力的螺[1－氮杂二环[2.2.2]辛烷－3,5’－噁唑烷]－2’－酮衍生物 |
| MXPA06003196A (es) | 2003-09-25 | 2006-06-23 | Astrazeneca Ab | Ligandos. |
| CN100494202C (zh) | 2003-10-21 | 2009-06-03 | 阿斯利康(瑞典)有限公司 | 螺呋喃并吡啶芳基衍生物 |
| US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050137217A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | Spirocyclic quinuclidinic ether derivatives |
| US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| US20050137398A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
| JP2007520527A (ja) * | 2004-02-04 | 2007-07-26 | ノイロサーチ アクティーゼルスカブ | ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式アリール誘導体 |
| JP2007534692A (ja) | 2004-04-22 | 2007-11-29 | メモリー・ファーマシューティカルズ・コーポレイション | インドール、１ｈ−インダゾール、１，２−ベンズイソキサゾール、１，２−ベンゾイソチアゾール、ならびにその調製および使用 |
| US7632831B2 (en) | 2004-05-07 | 2009-12-15 | Memory Pharmaceuticals Corporation | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
| CN101035792B (zh) * | 2004-10-20 | 2010-09-15 | 神经研究公司 | 新颖的二氮杂双环芳基衍生物和它们的医药用途 |
| WO2006065209A1 (en) | 2004-12-15 | 2006-06-22 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| RU2418797C2 (ru) * | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
| EP1891036A4 (en) | 2005-06-07 | 2010-08-04 | Univ Florida | SELECTIVE LIGANDS FOR ALPHA-7 NICOTINE RECEPTORS |
| DE602006017235D1 (de) * | 2005-08-22 | 2010-11-11 | Targacept Inc | Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung |
| CA2622677A1 (en) | 2005-09-23 | 2007-04-05 | Richard Schumacher | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| US8316104B2 (en) * | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| SA08290475B1 (ar) * | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| RU2481123C2 (ru) * | 2008-02-13 | 2013-05-10 | Таргасепт, Инк. | Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств |
-
2008
- 2008-07-03 SA SA08290475A patent/SA08290475B1/ar unknown
- 2008-07-31 TW TW102135271A patent/TW201402116A/zh unknown
- 2008-07-31 TW TW102135272A patent/TW201402117A/zh unknown
- 2008-07-31 TW TW097129030A patent/TWI429435B/zh not_active IP Right Cessation
- 2008-08-01 NZ NZ582986A patent/NZ582986A/en not_active IP Right Cessation
- 2008-08-01 SA SA112330303A patent/SA112330303B1/ar unknown
- 2008-08-01 NZ NZ582828A patent/NZ582828A/en not_active IP Right Cessation
- 2008-08-01 CN CN200880101593A patent/CN101868237A/zh active Pending
- 2008-08-01 BR BRPI0815009-5A2A patent/BRPI0815009A2/pt not_active IP Right Cessation
- 2008-08-01 WO PCT/US2008/071893 patent/WO2009018511A2/en not_active Ceased
- 2008-08-01 EP EP11194161.3A patent/EP2465501B1/en active Active
- 2008-08-01 DK DK08782584.0T patent/DK2182949T3/da active
- 2008-08-01 AU AU2008283813A patent/AU2008283813A1/en not_active Abandoned
- 2008-08-01 PH PH1/2012/501513A patent/PH12012501513A1/en unknown
- 2008-08-01 DK DK11194142.3T patent/DK2431037T3/en active
- 2008-08-01 PE PE2012000921A patent/PE20121821A1/es not_active Application Discontinuation
- 2008-08-01 PT PT87825840T patent/PT2182949E/pt unknown
- 2008-08-01 AR ARP080103348A patent/AR067775A1/es not_active Application Discontinuation
- 2008-08-01 EP EP12164661A patent/EP2484363A1/en not_active Withdrawn
- 2008-08-01 MX MX2010001293A patent/MX2010001293A/es not_active Application Discontinuation
- 2008-08-01 KR KR1020107004202A patent/KR20100063043A/ko not_active Withdrawn
- 2008-08-01 JP JP2010520219A patent/JP2010535252A/ja active Pending
- 2008-08-01 ES ES11194161.3T patent/ES2606752T3/es active Active
- 2008-08-01 EP EP11194142.3A patent/EP2431037B1/en active Active
- 2008-08-01 KR KR1020107004216A patent/KR20100051684A/ko not_active Ceased
- 2008-08-01 CN CN200880103971.1A patent/CN101784273B/zh not_active Expired - Fee Related
- 2008-08-01 EP EP08782584A patent/EP2182949B1/en active Active
- 2008-08-01 CA CA2694510A patent/CA2694510A1/en not_active Abandoned
- 2008-08-01 PE PE2008001292A patent/PE20090566A1/es not_active Application Discontinuation
- 2008-08-01 MY MYPI2010000501A patent/MY148002A/en unknown
- 2008-08-01 WO PCT/US2008/071872 patent/WO2009018505A1/en not_active Ceased
- 2008-08-01 PL PL08782584T patent/PL2182949T3/pl unknown
- 2008-08-01 BR BRPI0814889A patent/BRPI0814889A2/pt not_active IP Right Cessation
- 2008-08-01 CA CA2694504A patent/CA2694504C/en not_active Expired - Fee Related
- 2008-08-01 CL CL2008002271A patent/CL2008002271A1/es unknown
- 2008-08-01 CN CN201611140124.5A patent/CN106831755A/zh active Pending
- 2008-08-01 ES ES11194142.3T patent/ES2611139T3/es active Active
- 2008-08-01 MX MX2012009258A patent/MX346748B/es unknown
- 2008-08-01 MX MX2012009257A patent/MX346451B/es unknown
- 2008-08-01 AU AU2008283807A patent/AU2008283807B2/en not_active Ceased
- 2008-08-01 US US12/184,312 patent/US7981906B2/en active Active
- 2008-08-01 EP EP11075209A patent/EP2409703A1/en not_active Withdrawn
- 2008-08-01 JP JP2010520213A patent/JP5358573B2/ja active Active
- 2008-08-01 ES ES08782584T patent/ES2415107T3/es active Active
- 2008-08-01 ME MEP-2013-28A patent/ME01508B/me unknown
- 2008-08-01 EP EP08782589A patent/EP2185152A2/en not_active Withdrawn
- 2008-08-01 PH PH1/2012/501514A patent/PH12012501514A1/en unknown
- 2008-08-01 SI SI200830931T patent/SI2182949T1/sl unknown
- 2008-08-01 CN CN2013100489009A patent/CN103172628A/zh active Pending
- 2008-08-01 HU HUE11194142A patent/HUE030387T2/en unknown
- 2008-08-01 RS RS20130115A patent/RS52743B/sr unknown
- 2008-08-01 US US12/674,327 patent/US20110124678A1/en not_active Abandoned
- 2008-08-01 PE PE2012000920A patent/PE20121820A1/es not_active Application Discontinuation
- 2008-08-01 HR HRP20130286AT patent/HRP20130286T1/hr unknown
- 2008-08-01 UY UY0001031265A patent/UY31265A/es not_active Application Discontinuation
-
2010
- 2010-01-18 NO NO20100078A patent/NO20100078L/no not_active Application Discontinuation
- 2010-01-18 NO NO20100077A patent/NO20100077L/no not_active Application Discontinuation
- 2010-01-29 ZA ZA2010/00719A patent/ZA201000719B/en unknown
- 2010-03-02 CO CO10024587A patent/CO6260081A2/es not_active Application Discontinuation
- 2010-03-02 CO CO10024579A patent/CO6260080A2/es not_active Application Discontinuation
- 2010-03-02 EC EC2010010007A patent/ECSP10010007A/es unknown
- 2010-03-02 EC EC2010010008A patent/ECSP10010008A/es unknown
-
2011
- 2011-05-26 US US13/116,163 patent/US8119659B2/en active Active
- 2011-05-26 US US13/116,080 patent/US8541446B2/en active Active
-
2012
- 2012-04-02 IL IL218976A patent/IL218976A0/en not_active IP Right Cessation
- 2012-06-04 AU AU2012203288A patent/AU2012203288B2/en not_active Ceased
- 2012-09-19 RU RU2012140182/15A patent/RU2012140182A/ru not_active Application Discontinuation
- 2012-09-19 RU RU2012140148/15A patent/RU2012140148A/ru not_active Application Discontinuation
-
2013
- 2013-01-30 CY CY20131100081T patent/CY1113561T1/el unknown
- 2013-07-17 JP JP2013148087A patent/JP5852611B2/ja active Active
- 2013-07-17 JP JP2013148091A patent/JP6106549B2/ja active Active
- 2013-07-22 US US13/947,157 patent/US8846715B2/en active Active
- 2013-08-02 CL CL2013002227A patent/CL2013002227A1/es unknown
- 2013-08-02 CL CL2013002226A patent/CL2013002226A1/es unknown
-
2014
- 2014-08-25 US US14/467,289 patent/US20150045386A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6260081A2 (es) | Un medicamento para tratar o prevenir trastornos metabolicos que contiene un agonista nachr (alfa)7 selectivo | |
| BR112022018646A2 (pt) | Composto agonista do receptor glp-1, composição farmacêutica compreendendo o mesmo, métodos para preparar o composto e uso do dito composto para prevenir ou tratar uma doença metabólica ou uma doença neurodegenerativa | |
| AR109590A2 (es) | Régimen posológico para inhibidores de comt | |
| CO6251212A2 (es) | Tratamiento terapeutico de sindrome metabolico diabetes tipo 2 obesidad o prediabetes | |
| ECSP109977A (es) | Composición farmacéutica que comprende un derivado de benceno sustituido con glucopiranosilo. | |
| CO6430453A2 (es) | Terapia de combinacion para el tratamiento de la diabetes | |
| EA201101187A1 (ru) | Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами | |
| ECSP088628A (es) | Moduladores de receptores cannabinoides | |
| UY31295A1 (es) | Composicion farmacéutica que comprende un inhibidor de sglt2 | |
| AR083679A1 (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos | |
| UY32441A (es) | Composicion farmaceutica, metodos de tratamiento y sus usos | |
| PE20050249A1 (es) | Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos | |
| CL2007003352A1 (es) | Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen | |
| UY30686A1 (es) | "receptor nicotinico de acetilcolina, subtipo selectivo de amidas de diazabiciloalcanos" | |
| UY31291A1 (es) | Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido | |
| AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
| CL2008002916A1 (es) | Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros. | |
| CL2023003662A1 (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina | |
| CL2021000030A1 (es) | Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales | |
| GT200800307A (es) | 18-metil-19-nor-androst-4-en-17,17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen | |
| CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| CO6400019A1 (es) | Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion | |
| PA8787001A1 (es) | " derivados de macrolactona" | |
| MX2018012439A (es) | Composiciones y metodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotinico. | |
| MX2024003112A (es) | Compuestos de beta-lactama o sales de los mismos para su uso en la prevencion o tratamiento de accion prolongada del trastorno del metabolismo de la glucosa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |